Stroke associated with Mycoplasma hominis infection: a case report

Anthoula C Tsolaki,Despina Georgiadou,Thomas Tegos,Galaktion Konstantinidis,Fotini Michali,Nikolaos D Michalis,Stavroula Koukou

doi:10.1186/s13256-021-02903-5

Abstract

BackgroundMycoplasmas are the smallest prokaryotic microorganisms in nature. Many cases of stroke post-Mycoplasma pneumoniae infection have been reported, particularly in the pediatric population. However, Mycoplasma hominis infection has not previously been associated with stroke.Case presentationWe report the case of a 36-year-old Greek woman who presented with an extensive stroke with an unspecified cause. She had a concurrent genital infection with Mycoplasma hominis for an unknown duration.ConclusionAn association may exist between stroke and the immune response to Mycoplasma hominis infection.

Highlights

Stroke is a leading cause of preventable death and adult disability
An association may exist between stroke and the immune response to Mycoplasma hominis infection
Multiple literature descriptions exist of strokes post-Mycoplasma pneumoniae (MP) infection, in the pediatric population [4,5,6]

Summary

Introduction

Stroke is a leading cause of preventable death and adult disability. Infections have been associated with stroke but are not considered directly causal. Her discharge medication included doxycycline at 200 mg/day twice orally for 14 days; isoconazole nitrate and diflucortolone valerate for external use for 7 days; and fluconazole at 150 mg/day orally for 14 days because of Candida non-albicans co-infection During her hospitalization, she received oral metoprolol at 100 mg, 1⁄4 b.i.d. because of her persisting tachycardia after cardiology consultation, acetylsalicylic acid at 100 mg once daily for secondary stroke prevention, folic acid at 5 mg once daily, hydroxocobalamin IM once/ month, omeprazole at 40 mg once daily, risperidone at 1 mg 1⁄2 t.i.d., sertraline at 100 mg once daily, given for her neuropsychiatric symptoms. In the recent 2-year follow-up, the patient’s behavior had improved, no other cerebrovascular events had occurred, and her medication was modified to rosuvastatin at 10 mg once daily, acetylsalicylic acid at 100 mg once daily, lisinopril at 20 mg once daily, lansoprazole at 20 mg once daily and quetiapine at 25 mg once daily

Discussion

Conclusion